We used limbic seizures induced in rats by systemic injection of the cholinergic agonist pilocarpine (380 mg/kg; i.p.) to study the neuronal pathways within the basal ganglia that modulate seizure threshold. N-Methyl-D-aspartate (N-Me-D-Asp) is an excitatory amino acid derivative that is a powerful convulsant agent when injected into the cerebral cortex, amygdala, or hippocampus in rats. Bilateral microinjections of N-Me-D-Asp into the caudate-putamen, however, protected against limbic seizures induced by pilocarpine (injected systemically), with an ED50 of 0.7 nmol (range 0.5-1.0 nmol). Lesioning the caudate-putamen (by bilateral microinjection of the excitotoxin ibotenate) converted subconvulsant doses of pilocarpine into convulsant ones. The anticonvulsant action of N-Me-D-Asp in the caudate-putamen was reversed by blocking y-aminobutyrate-mediated inhibition in the substantia nigra pars reticulata or in the entopeduncular nucleus. The results suggest that the caudate-putamen and its y-aminobutyrate-dependent efferent pathways modulate the threshold for seizures in the limbic forebrain.
The function of the basal ganglia in the spread of seizures within the forebrain has interested neurologists, neurosurgeons, and neuropathologists since the 19th century (1) . Clinical observations in humans and lesion studies in monkeys and dogs established that the globus pallidus (GP) and the substantia nigra (SN) serve as relay stations in the propagation of seizures elicited from the motor cortex or the limbic system (2, 3) . However, the precise pathways in the basal ganglia that are involved in the spread of seizures and the specific neurotransmitters used in these pathways have not been identified.
The SN has been proposed as a key site at which the anticonvulsant activity of drugs that enhance y-aminobutyric acid (GABA)-mediated inhibition is expressed (4, 5) . Excitation within the SN is probably mediated by dicarboxylic amino acids (L-glutamate or L-aspartate). Blockade of excitatory neurotransmission in the SN by 2-amino-7-phosphonoheptanoate, an antagonist that acts selectively at the receptor site sensitive to N-methyl-D-aspartate (N-Me-D-Asp), raises the threshold for seizures and curtails their motor expression (6, 7) .
Temporal lobe, or "psychomotor," epilepsy is the most common form of epilepsy in humans (8) . Prolonged limbic seizures in animals and humans result in selective damage to the forebrain, involving hippocampus, amygdala, and sometimes the thalamus (9) . This form of epilepsy is particularly resistant to anticonvulsant medication and represents a major therapeutic problem (10) .
Seizures produced by pilocarpine in rats provide an animal model of temporal lobe epilepsy that permits the evaluation of behavioral, electroencephalographic, and morphological sequelae of intractable limbic convulsions (11) (12) (13) . This experimental model of epilepsy serves to delineate the anatomical substrates essential for the motor expression of seizures (7, 14) .
We recently observed that microinjections of the GABA agonist muscimol or an irreversible inhibitor of GABA transaminase, -y-vinyl-GABA, into the rat substantia nigra pars reticulata (SNR) or entopeduncular nucleus (EP) protect against the convulsant action of pilocarpine (14, 15) . These findings suggested that GABAergic afferents to the SNR and to the EP produce an anticonvulsant action. We now present evidence that pathways linking the striatum and either SNR or EP may regulate the seizure threshold of the limbic forebrain. We have observed alterations in the behavioral, electroencephalographic, and morphological sequelae of seizures produced by pilocarpine following the bilateral microinjection of N-Me-D-Asp into different subregions of the rat caudate-putamen, nucleus accumbens, and GP.
MATERIALS AND METHODS
Male Wistar rats (230-250 g) were anesthetized with sodium pentobarbital (Nembutal; Ceva, Watford, UK; 50 mg/kg, i.p.) and chronically implanted with guide cannulae directed toward the caudate-putamen, nucleus accumbens, GP, SNR, and EP. Coordinates for microinjections into the caudateputamen, nucleus accumbens, GP, SNR, and EP, derived from the atlas of Konig and Klippel (16), were as follows. Caudate-putamen A 9410: AP 9.41, L 1.0 to 2.6, V +2.0 to 0.6. Caudate-putamen A 7890: AP 7.89, L 1.0 to 3.6, V -1.0 to +2.2. Caudate-putamen A 6360: AP 6.36, L 2.0 to 4.5, V -1.6 to +2.0. Nucleus accumbens: AP 9.41, L 0.6 to 1.6, V -1.0 to 0.0. GP: AP 6.36, L 2.0 to 3.0, V -1.6 to +0.2. SNR: AP 1.61, L 1.9, V -2.6. EP: AP 4.89, L 2.4, V -1.8. The microinjections into the caudate-putamen, nucleus accumbens, GP, SNR, and EP were performed bilaterally in unanesthetized rats. The drugs were delivered into the caudate-putamen, nucleus accumbens, and GP in a volume of 0 injected into the caudate-putamen in the dose of 5 nmol, 15 min before i.p. injection ofpilocarpine hydrochloride (Sigma; 380 mg/kg). N-Me-D-Asp (2 nmol) and 2-amino-7-phosphonoheptanoate (2 nmol) were coadministered into the ventral part of the caudate-putamen 15 min before pilocarpine (380 mg/kg). Bicuculline methiodide (Pierce) was administered bilaterally into the SNR in doses of 10 and 50 pmol or into the EP in the dose of 10 pmol. Ibotenic acid (Sigma; 30 nmol) was microinjected bilaterally into the caudate-putamen (A 7890) at coordinates AP 7.89, L 2.6, V + 1.4 and -0.6 (17) . The drug was delivered in a volume of 0.5 ,/1 at a rate of 0.1 ,u1/min.
After surgery, animals were housed individually and were allowed to recover for a period of 10-14 days (17) . Methylscopolamine nitrate (Sigma; 1 mg/kg) was administered s.c. 30 min before injection of pilocarpine, to limit peripheral toxic effects (11) . N-Me-D-Asp, 2-amino-7-phosphonoheptanoate, and ibotenic acid were dissolved in 1 M NaOH, and the solutions were diluted with 0.9% NaCl (pH adjusted to 7.35 with 0.2 M HCl). Pilocarpine, methylscopolamine, and bicuculline methiodide were dissolved in 0.9% NaCl. No rats were used for more than one microinjection. The brains were processed for morphological examination by light microscopy 1-3, 5-15, or 21-45 days after administration of pilocarpine. The rats were anesthetized with an overdose of sodium pentobarbital and perfused with a fixative containing 10% acetic acid, 10% formaldehyde, and 80% methanol. The brains were allowed to fix in situ at 4°C for 24 hr and then were removed and processed for paraffin embedding. Subsequently, serial sections of the entire brain were cut coronally at 10 ,um, and every 10th section was mounted on a glass slide and stained with cresyl violet or according to the Fink and Heimer technique (20) . (Fig. 1) . Microinjections of N-Me-D-Asp (2 nmol) into the nucleus accumbens (n = 4) and GP (n = 7) did not result in an anticonvulsant effect (Fig. 1) .
Electrographic monitoring showed that microinjections of N-Me-D-Asp (2 nmol) into the ventral and posterior caudateputamen blocked the development of seizure activity produced by pilocarpine (380 mg/kg) (n = 13) (Fig. 2) . Microinjections of N-Me-D-Asp (2 nmol) (n = 7) into the anterior and dorsal caudate-putamen did not alter the development of seizures as revealed by electroencephalography. Morphological analysis of the brains revealed definite protection against the seizure-related brain damage after microinjections of N-Me-D-Asp (2 nmol) into the ventral and posterior caudate-putamen (Fig. 1 parts of the caudate-putamen (n = 6) did not affect seizures produced by pilocarpine (380 mg/kg).
To characterize the pathway specificity of the anticonvulsant action ofN-Me-D-Asp in the caudate-putamen, eight rats were injected with N-Me-D-Asp (2 nmol) into the ventral part of the nucleus (A 7890) and subsequently given pilocarpine (380 mg/kg). One week later, ibotenate (60 nmol) was microinjected into the caudate-putamen at the same coordinates from which an anticonvulsant effect of N-Me-D-Asp was achieved. After 2 weeks of recovery, pilocarpine (250 mg/kg) was injected in these animals. Five out of eight lesioned rats developed typical limbic seizures and status epilepticus that resulted in seizure-related brain damage in response to this dose of pilocarpine. In sham-operated rats (n = 6), pilocarpine (250 mg/kg) was nonconvulsant.
To characterize the neurotransmitter specificity of the anticonvulsant action of N-Me-D-Asp in the caudate-putamen and the proconvulsant effects of caudate-putamen lesions with ibotenate, we examined whether blockade of GABAergic transmission within the SNR and EP attenuates the anticonvulsant effect of N-Me-D-Asp. Bicuculline methiodide (10 
DISCUSSION
The results show that an increase in the net excitation in the caudate-putamen results in an anticonvulsant effect. An anticonvulsant effect of N-Me-D-Asp in the rat caudateputamen was detectable throughout the entire extent of the nucleus. However, the predominant effect was elicited from the ventral and posterior part of the caudate-putamen.
Microinjections of N-Me-D-Asp into the caudate-putamen not only blocked the motor expression ofpilocarpine-induced seizures but also prevented the evolution of paroxysmal electrographic activity in the hippocampus and cortex, as well as totally prevented the seizure-related brain damage. Furthermore, chemical lesions destroying the output neurons located in the medial part of the caudate-putamen lowered the threshold for seizures produced by pilocarpine. The anticonvulsant effect of N-Me-D-Asp in the caudateputamen was abolished by blockade of GABA-mediated inhibition in the SNR and EP (nuclei receiving efferent projections from the caudate-putamen). These observations suggest that excitatory amino acid neurotransmission within the caudate-putamen modulates the seizure threshold of the limbic system, and they define the striatal output pathways that are responsible for this effect. These findings form an interesting parallel to electrical-stimulation studies that indicated a possible role for the caudate nucleus in the control of convulsive activity in the amygdala, hippocampus, and temporal cortex in cats and dogs (21) argues against a preferential role for the SN in gating the expression of seizure activity. The SN and EP both undergo irreversible degeneration in rats subjected to status epilepticus, whereas striatum is resistant to epilepsy-related cell damage (9, 22) . Similarly, the caudate-putamen is remarkably resistant to the generation of kindled seizures (18) . Excitatory neurotransmission in the caudate-putamen, the SN, and the EP participates in the regulation of the final set-point of the respective output neurons, thus providing modulation of the passage of information through the basal ganglia (23) . Excitatory neurotransmission in the basal ganglia is involved in the fine processing of the sensory and motor information required for integration of the neocortex, limbic forebrain, and spinal motor centers.
The basal ganglia provide a center for communication between the sensorimotor cortex and the limbic system and thus participate both in the propagation of motor seizures to the executive targets and in the generation of the seizure activity within the limbic centers.
Our findings demonstrate that both of these aspects of epileptogenesis are subject to control by excitation and inhibition within the striatum and its efferent pathways.
